Ignite Creation Date:
2024-05-05 @ 11:59 AM
Last Modification Date:
2024-10-26 @ 9:18 AM
Study NCT ID:
NCT00203177
Status:
COMPLETED
Last Update Posted:
2010-03-09
First Post:
2005-09-13
Brief Title:
Rasagiline in Advanced Parkinsons Disease Patients With Motor Fluctuations Treated With LevodopaCarbidopa Therapy
Sponsor:
Teva Branded Pharmaceutical Products RD Inc
Organization:
Teva Branded Pharmaceutical Products RD Inc
Study Overview
Official Title:
A Bi-national Multicenter Double-Blind Randomized Study to Evaluate the Safety and Tolerability of Rasagiline Mesylate in Advanced Parkinsons Disease PD Patients With Motor Fluctuations Treated With Chronic LevodopaCarbidopa Therapy
Status:
COMPLETED
Status Verified Date:
2010-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Study to look at the effectiveness tolerability and safety of two doses of Rasagiline 05 mg and 1mg in advanced Parkinsons Disease PD Patients who have been treated with LevodopaCarbidopa therapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None